ASCO recently announced the formation of an important new position within ASCO, that of a Chief Medical Officer (CMO). After a six-month search, a five-person committee comprised of ASCO Board of Directors members chose Richard L. Schilsky, MD, to fulfill this key role. Dr. Schilsky comes to ASCO as Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center. He will be joining the ASCO staff on February 28, 2013.

Dr. Schilsky is a former ASCO president (2008-2009) and a highly respected leader in the field of clinical oncology, specializing in new drug development and treatment of gastrointestinal cancers. As a past Board member; former Chair of ASCO's Cancer Research, Communications, and Government Relations Committees; and a current member of the Conquer Cancer Foundation Board, Dr. Schilsky brings with him a firm grasp of the organization including its history, mission, structure, and operations.

The Chief Medical Officer position will report directly to the CEO, Allen S. Lichter, MD, and support the President, volunteer leadership, CEO, and staff in communicating and carrying out the overall strategic priorities of the organization.

"Rich has that rare combination of clinical expertise, a formidable research track record, and a warmth and humanity that make him perfect for this role," said Sandra M. Swain, MD, FACP, ASCO President and Chair of the CMO Search Committee. "Having led many of ASCO's most important efforts and committees over the years, he is also intimately familiar with ASCO's programs, staff, and member needs. As President, I look forward to working with him. I am sure he will provide wise counsel as we advance ASCO's mission."

Expanded efforts

ASCO has branched into new areas in recent years, and the Board decided it was time to bring on another experienced senior member of the staff leadership team to provide additional insight and guidance.

"I look forward to welcoming Rich to our team during this very exciting time in cancer science and this very challenging time in cancer medicine when all of us must look harder at the quality and value of care we provide," said Dr. Lichter.